Hypersensitivity reactions to oxaliplatin: clinical features and risk factors in Koreans.
نویسندگان
چکیده
BACKGROUND AND AIM Oxaliplatin hypersensitivity is a well-known adverse reaction but the prevalence varies and data for frequency and clinical features have not been reported for Korea. Here we evaluates the prevalence and risk factors for hypersensitivity reactions to oxaliplatin after chemotherapy. METHODS Clinical information on all patients treated with oxaliplatin was retrospectively reviewed in electronic medical records between August 2009 and July 2010 in Seoul National University Bundang Hospital. Patients who experienced hypersensitivity reactions to oxaliplatin were compared with those who did not. RESULTS A total of 393 patients received oxaliplatin, with 42 (10.7%) experiencing hypersensitivity reactions including three cases of anaphylaxis. Median cycle of the first hypersensitivity reaction was 8. Reactions correlated with lower dexamethasone doses. Other variables were not significant. CONCLUSIONS The prevalence of hypersensitivity reactions was 10.7%, symptoms being mostly mild and cutaneous. Lower dexamethasone doses could be a predictor for hypersensitivity reactions to oxaliplatin.
منابع مشابه
Hypersensitivity reactions to oxaliplatin: experience in a single institute.
BACKGROUND A rising incidence of hypersensitivity reactions to oxaliplatin has been observed as a result of increasing clinical use. Epidemiological and clinical features of these reactions are reviewed. PATIENTS AND METHODS Records of patients treated with a modified FOLFOX regimen from March 1999 to March 2004 were reviewed. RESULTS One hundred and eighty patients were identified. Twenty-...
متن کاملRisk Factors for Oxaliplatin-Induced Hypersensitivity Reactions in Japanese Patients with Advanced Colorectal Cancer
OBJECTIVE Previously, we suggested that oxaliplatin (L-OHP)-related grade 3/4 hypersensitivity reactions occurred immediately after the initiation, but grade 1/2 reactions did not. This study was conducted to clarify the risk factors for L-OHP-related hypersensitivity reactions. METHODS Clinical data from 108 Japanese patients with colorectal cancer were analyzed, who were treated with L-OHP-...
متن کاملClinical Features of Oxaliplatin Induced Hypersensitivity Reactions and Therapeutic Approaches.
Oxaliplatin, a third generation novel platinum compound is the most effective first line chemotherapeutic agent for colorectal cancer (CRC) in combination with 5FU and leucovorin. It is indicated for pancreatic, gastric and testicular cancers combined with bevacuzimab, capecitabine, irinotecan and other cytotoxic agents. However, moderate to severe hypersensitivity reactions (HSR) during or aft...
متن کاملClinical features of hypersensitivity reactions to oxaliplatin among Chinese patients with colorectal cancer
Oxaliplatin is a thirdgeneration platinum antineoplastic agent. The 2aminocyclohexaneplatinum DNA that oxaliplatin forms is more hydrophobic than that formed by cisplatin and carboplatin. 1 The renal toxicity of oxaliplatin is milder than cisplatin, while its bone marrow suppression action is weaker than carboplatin. Nervous system toxicity is the main doselimiting side effect for oxalipla...
متن کاملA New Practical Desensitization Protocol for Oxaliplatin-Induced Immediate Hypersensitivity Reactions: A Necessary and Useful Approach.
BACKGROUND AND OBJECTIVE Desensitization protocols for patients with immediate hypersensitivity reactions (IHSRs) have proven to be effective, but they are not widely used in clinical practice because of impracticalities such as high cost, long procedure duration, and a lack of trained personnel. We aimed to determine the clinical characteristics of oxaliplatin-induced IHSRs and assess measures...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Asian Pacific journal of cancer prevention : APJCP
دوره 13 4 شماره
صفحات -
تاریخ انتشار 2012